



ELAROS: An Incubator and Product Accelerator

Development of a digital clinical assessment toolkit and A case study describing how new products and projects have benefitted from input from ELAROS



Background

ELAROS' incubator and product accelerator model acts as a 'wrap around' in terms of partnering, finding funding, people development, product development, navigating regulations and commercialisation, bringing benefits to Elaros and the participants involved.

This case study describes how new products and projects have benefited from input from ELAROS.



Neu-Restore: A digital stroke assessment and rehabilitation platform




ELAROS is a collaborative organisation and keen participant in research projects bringing its expertise in the development of digital solutions to many clinical areas.

ELAROS is proactive in scoping out new collaborations and partnerships and offers to incubate or accelerate the ideas of others.



ELAROS' incubator/accelerator assessment criteria



The Neu-Restore project was an Innovate UK funded study which focussed on the common long-term effects of stroke on the upper limb.

Stroke assessment and rehabilitation rely heavily on subjective observations. Clinicians need more reliable and predictive tools to support decision-making. The Neu-Restore project developed a digital hub for the management of the upper limb following a stroke.

Neu-Restore is a device, consisting of a mobile phone that collects electromyography (EMG) data from a hardware module which makes possible, portable EMG based assessments.

Dr Tom Richards, Post Doctoral Research Associate, University of Exeter.

"Working with ELAROS has been good in that it has helped me get a better understanding of the endpoints of research and what is required to develop an idea, get insights into business and build a strong network"



Neu-Restore provides all the tools that are needed by staff, patients, and carers on one platform to assist with clinical management, support, and the practical aspects of stroke care.

The benefit for Dr Richards and the Neu-Restore project in working with ELAROS was that the company was able to take the concept from the academic environment, into the healthcare/ industrial ecosphere and onto the pathway to commercialisation.

MoRIS: Early Autism detection in children aged 12 to 36m

Autism diagnosis rates have increased over the past two decades due to better recognition but delays in diagnosis hinder timely support. Evidence shows that an early lack of interest in faces and people is a strong predictor of autism and that children who do not speak by the age of five are more likely to face difficulties with communication later. It is known that autistic children often show more interest in systems and patterns, from an early age, than non-autistic children.

Geoff Morgan
Head of Educational Psychology,
University of Bradford



"Blesson [from ELAROS] as Project Manager for MoRIS has skilfully coordinated the process of turning sets of ideas and sketches into a product specification. It has been an exciting journey so far and this product could change the lives of thousands of children and families"

The current system for assessment of autism is very resource intensive & time consuming. Early detection & support is important.

Geoff worked with ELAROS' team members, Blesson Ezra and Toby Boud to develop an application for an NIHR grant. This project, Monitoring of Repetitive Interest and Social-communication (MoRIS) aims to develop a prototype system using available technology and a combination of questionnaires and monitoring young childrens' eye gaze while watching animations to evaluate what type of events capture their interest.

ParkinSense: Detecting Parkinson's earlier, faster and more accurately

Parkinson's is a progressive neurological condition that causes nerve cells in parts of the brain to die, leading to symptoms that include problems with movement, tremors, stiffness and impaired balance.

Parkinson's lacks an objective and accessible diagnostic test, relying on clinical observation of motor symptoms that appear only after major neuronal loss. This delay causes frequent misdiagnosis, late intervention, and poorer outcomes. It is estimated that Parkinson's takes three years to diagnose and in 2024, cost the UK economy £3.6 billion

Adam Lockhart, Scientific Director, Parkinsense

"Working with ELAROS has enabled me to gain perspective on how medtech tools are built and how it is different from a conventional technology projects. I am keen to get this technology into the hands of people who need it most as I believe ParkinSense could make a real impact and I am excited to see where it goes!"



The system for assessment of autism is currently very resource intensive and time consuming, early detection and support is important.

Geoff worked with ELAROS' team members, Blesson Ezra and Toby Boud to develop an application for an NIHR grant. This project, Monitoring of Repetitive Interest and Social-communication (MoRIS) aims to develop a prototype system using currently available technology and a combination of questionnaires and monitoring young childrens' eye gaze while watching animations to evaluate what type of events capture their interest.

About ELAROS

ELAROS is a globally connected digital health SME based in Sheffield, UK, that was incorporated in 2010, backed by private investors and with four NHS organisations as shareholders.

ELAROS is a health company rather than a technology company. Its work is collaboration driven and unmet needs led, rather than technology push.

The company is agile, small enough to respond quickly but big enough and connected enough to be able to deliver nationally and internationally.

"Ideas and opportunities come from everywhere and nowhere in particular. It's all about being proactive" Professor Paul O'Brien, CEO ELAROS.

Contact

Email: hello@elaros.com

Electric Works,

3 Concourse Way

Sheffield. S1 2BJ

Website: [ELAROS](#)

[LinkedIn](#) | [Linktree](#)

Author: Dr Claire Horton

Copyright: ELAROS 24/7 Ltd 2026

